Therefore, antibodies directed against PD-1 expressed on T cells and/or antibodies directed against PD-L1 expressed on tumor cells, preventing the ligand-receptor binding could ‘release the brake’ and permit T cell activation. This evidence concerns the gene CD274 and neoplasm.